These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1134 related articles for article (PubMed ID: 6895729)

  • 1. Combination chemotherapy with AMSA on L1210 leukaemia and B16 melanoma.
    Dumont P; Atassi G; Tagnon HJ
    Eur J Cancer Clin Oncol; 1981 Sep; 17(9):1017-21. PubMed ID: 6895729
    [No Abstract]   [Full Text] [Related]  

  • 2. Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicity.
    Hornedo J; Van Echo DA
    Pharmacotherapy; 1985; 5(2):78-90. PubMed ID: 2582401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of gamma-irradiation with two new antineoplastic agents, aziridinylbenzoquinone (AZQ) and 4'- (acridinylamino)methanesulfon-m-anisidide (AMSA), in murine tumors in vivo.
    Johnson RK; Wodinsky I; Swiniarski J; Meaney KF; Clement JJ
    Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1605-9. PubMed ID: 583418
    [No Abstract]   [Full Text] [Related]  

  • 4. Clonal variation in the sensitivity of B16 melanoma to m-AMSA.
    Stephens TC; Peacock JH
    Br J Cancer; 1982 Jun; 45(6):821-9. PubMed ID: 6896455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amsacrine (AMSA).
    Issell BF
    Cancer Treat Rev; 1980 Jun; 7(2):73-83. PubMed ID: 6931632
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential antitumor agents. 38. 3-substituted 5-carboxamido derivatives of amsacrine.
    Denny WA; Atwell GJ; Baguley BC
    J Med Chem; 1983 Nov; 26(11):1619-25. PubMed ID: 6688829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of AMSA in patients with metastatic malignant melanoma.
    Houghton AM; Camacho F; Wittes R; Young CW
    Cancer Treat Rep; 1981; 65(1-2):170-1. PubMed ID: 6894401
    [No Abstract]   [Full Text] [Related]  

  • 8. The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study.
    Amrein PC; Poulin RF; Coleman M; Richards F; Weil M; Kennedy BJ; Carey RW; Green MR; Holland JF; Weinberg V
    Am J Clin Oncol; 1984 Jun; 7(3):269-71. PubMed ID: 6547269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacarbazine and melphalan. Enhancement by dosage scheduling of the effect in combination treatment on the Harding-Passey melanoma in C3D2F1 mice.
    Hill HZ; Hill GJ; Szramowski J
    Arch Surg; 1979 Feb; 114(2):135-8. PubMed ID: 426619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumour activity of substituted 9-anilinoacridines--comparison of in vivo and in vitro testing systems.
    Baguley BC; Nash R
    Eur J Cancer (1965); 1981 Jun; 17(6):671-9. PubMed ID: 6895501
    [No Abstract]   [Full Text] [Related]  

  • 11. The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.
    Cain BF; Atwell GJ
    Eur J Cancer (1965); 1974 Aug; 10(8):539-49. PubMed ID: 4463003
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
    Creagan ET; Ahmann DL; Ingle JN; Purvis JD; Green SJ
    Cancer Treat Rep; 1981; 65(1-2):169. PubMed ID: 6894400
    [No Abstract]   [Full Text] [Related]  

  • 13. Antitumor activity of 1-nitro-9-aminoacridines including nitracrine against some ascitic experimental tumors.
    Mazerska Z; Lukowicz J; Konopa J
    Arzneimittelforschung; 1990 Apr; 40(4):472-7. PubMed ID: 2357249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acceleration of growth of transplantable tumors and change in the sensitivity to chemotherapy on administration of creatinine].
    Pukhal'skaia ECh; Platonova GN
    Biull Eksp Biol Med; 1971 Oct; 72(10):82-5. PubMed ID: 5126158
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
    Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
    Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amsacrine (AMSA)--a clinical review.
    Louie AC; Issell BF
    J Clin Oncol; 1985 Apr; 3(4):562-92. PubMed ID: 3884748
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
    Rose WC; Trader MW; Dykes DJ; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 Dec; 62(12):2085-93. PubMed ID: 751716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice.
    Baguley BC; Kernohan AR; Wilson WR
    Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1607-13. PubMed ID: 6688994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
    Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
    Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effects of antineoplastic agents and anti-lymphoma allograft reactions.
    Riccardi C; Bartocci A; Puccetti P; Spreafico F; Bonmassar E; Goldin A
    Eur J Cancer (1965); 1980 Jan; 16(1):23-33. PubMed ID: 7358077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 57.